A recent study has raised questions about a possible link between RSV vaccination during pregnancy and certain maternal or infant health conditions. Researchers analyzed health data from maternal vaccination programs and identified patterns that may link vaccination to specific outcomes in mothers and newborns.
RSV, or Respiratory Syncytial Virus, is a respiratory infection that can cause serious illness in infants, including Bronchiolitis and Pneumonia. To help protect newborns, the U.S. Food and Drug Administration approved maternal RSV vaccination in 2023. The vaccine works by allowing protective antibodies to pass from the pregnant mother to the baby before birth.
In the new research, scientists reviewed data to determine whether receiving the vaccine during pregnancy could influence the health of either the mother or the infant. The findings suggested possible associations with certain medical events, but the study did not establish a direct cause-and-effect relationship.
Researchers published the findings in 2026 as part of ongoing efforts to evaluate the safety of maternal vaccination programs. The analysis focused on health data from countries that have implemented RSV vaccination for pregnant women.
Scientists say the results add to a growing body of research examining both the benefits and potential risks of maternal vaccination. While the vaccine aims to reduce severe RSV infections in newborns, experts stress that additional studies are needed to better understand the patterns observed in the data.
Medical specialists emphasize that clinical research will continue to assess vaccine safety while also evaluating how maternal immunization can help protect infants during the first months of life, when they face the highest risk from RSV.
